Enhancing HCC recurrence prediction after liver transplantation: From DCP plus AFP-L3 model to GALAD score

AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantationJournal of HepatologyVol. 79Issue 6PreviewAlpha-fetoprotein (AFP) predicts hepatocellular carcinoma (HCC) recurrence after liver transplant (LT) but remains an imperfect biomarker. The role of DCP (des-gamma-carboxyprothrombin) and AFP-L3 (AFP bound to Lens culinaris agglutinin) in predicting HCC recurrence remains incompletely characterized. AFP-L3 and DCP could identify patients at high risk of post-transplant HCC recurrence and serve as liver transplant exclusion criteria to defer transplant until patients receive additional risk-reducing pre-transplant locoregional therapy. Full-Text PDF Dual Positivity for AFP-L3 and DCP Identifies Patients at Exceptionally High Risk for Post-LT HCC RecurrenceJournal of HepatologyPreviewNeil Mehta has served on advisory boards for WAKO Diagnostics and has received institutional research funding from WAKO Diagnostics, Glycotest, and Target Pharmasolutions. Francis Yao has received institutional research funding from WAKO Diagnostics. None of the other authors have any relevant potential conflicts of interest to disclose Full-Text PDF MH, FvB, and TB were responsible for the conceptualization and drafting of the manuscript. FvB has initiated the study. All authors, including AH and DS, critically reviewed and provided significant input to the manuscript. AH and DS also contributed to the data collection process. None. None. None. Quantification of AFP, AFP-L3 and DCP was provided by Fujifilm Wako Chemicals Europe, Neuss, Germany.